CD30, Recombinant, Human (TNFRSF8, Tumor Necrosis Factor Receptor Superfamily Member 8, CD30L Receptor, Ki-1 Antigen, Lymphocyte Activation Antigen CD30, D1S166E)

CD30, also known as Ki-1 antigen and , is a 120kD type I transmembrane glycoprotein belonging to the TNF receptor superfamily. Mature human CD30 consists of a 361aa extracellular domain with six cysteine-rich repeats, a 28aa transmembrane segment, and a 188aa cytoplasmic domain. In contrast, mouse and rat CD30 lack 90aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C-terminal 132aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells. However, it is up-regulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity. CD30 binds to CD30 Ligand/ TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells. CD30 signaling co-stimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response. In the absence of antigenic stimulation, it can still induce T cell expression of IL-13. CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells. In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5. An 85-90kD soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage. Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling.\n\nSource:\nRecombinant corresponding to aa1-369 from human TNFRSF8, expressed in mouse myeloma cell line, NS0.\n\nMolecular Weight:\n~38.4kD\n\nBiological Activity:\nMeasured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C2382-15

Size

100ug

Form

Supplied as a lyophilized powder in PBS. Reconstitute with PBS to 0.1mg/ml.

Purity

~95% (SDS-PAGE)

References

1. Kennedy, M.K. et al. (2006) Immunology 118:143. 2. Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267. 3. Durkop, H. et al. (1992) Cell 68:421. 4. Hamann, D. et al. (1996) J. Immunol. 156:1387. 5. Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147. 6. Gruss, H.-J. et al. (1994) Blood 83:2045. 7. Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174. 8. Del Prete, G. et al. (1995) J. Exp. Med. 182:1655. 9. Harlin, H. et al. (2002) J. Immunol. 169:2451. 10. Amakawa, R. et al. (1996) Cell 84:551. 11. Chiarle, R. et al. (1999) J. Immunol. 163:194. 12. Vinante, F. et al. (2002) Blood 99:52. 13. Hansen, H.P. et al. (1995) Int. J. Cancer 63:750. 14. Hansen, H.P. et al. (2000) J. Immunol. 165:6703. 15. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.